facility construction
Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.